38IS

Intellia Therapeutics Inc

38I.SG·Stuttgart

FollowCompareShare

10.200.00 (0.00%)today

As of Oct 19, 9:16 AM CEST · May be delayed up to 15 min · EUR

1D5D1M6MYTD1Y5Y10Y20YAll

MountainLineCandles

Indicators

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close10.20

Open10.28

Day range10.2010.28

52-week range6.9224.17

Off day high−0.78%

Off 52-week high−57.80%

Volume392

Avg. volume (3M)943

Market cap—

EPS (TTM)—

Forward P/E—

P/E ratio (TTM)—

Dividend yield—

Beta (5Y)—

Shares outstanding—

Short interest—

Earnings dateAug 6, 2026

Analyst target—

Profit margin—

Related companies

Compare ›

Moves togetherAlso watched

The stocks whose daily moves over the past year went most closely with 38I.SG's: the correlation of their daily returns, where 1 would be moving as one.

Company	Mkt cap	Price	Today
38IDIntellia Therapeutics Inc38I.DU · Correlation 0.81	—	10.22	+5.38%
1CGSCRISPR Therapeutics AG1CG.SG · Correlation 0.59	—	43.79	−5.03%
38IFIntellia Therapeutics Inc.38I.F · Correlation 0.46	1.37B	9.77	−2.30%

What visitors to 38I.SG's page also look at.

Company	Mkt cap	Price	Today
38IFIntellia Therapeutics Inc.38I.F	1.37B	9.77	−2.30%
38IDIntellia Therapeutics Inc.38I.DU	—	10.22	+5.38%
1CGSCRISPR Therapeutics AG1CG.SG	—	43.79	−5.03%

From the 4Search instruments index: what each company does (its business description), its industry, size, headquarters and the markets it serves; and from a year of daily prices, which move together. Prices may be delayed up to 15 min.

Latest news

All 38I.SG news ›

Markets Daily·9h agoPositive

Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)

Posted by Danessa Lincoln on Oct 19th, 2026 Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) and Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two…

Markets Daily·2d agoNegative

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Has Average Target Price of $20.72

Posted by Michael Walen on Oct 17th, 2026 Check Out Our Latest Report on Intellia Therapeutics NASDAQ NTLA opened at $11.42 on Friday. The company has a market cap of $1.60 billion, a PE ratio of -3.40 and a beta of 1.80. The stock’s 50…

GlobeNewswire News Room·6d ago

Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer

Intellia Therapeutics Appoints Jing L.

Defense World·Oct 8Negative

Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Barclays

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) was upgraded by investment analysts at Barclays to a “strong sell” rating in a report released on Tuesday, Marketbeat.com reports. The brokerage currently has a $8.00 price objective on…

Defense World·Oct 8

Intellia Therapeutics (NASDAQ:NTLA) Stock Picked Up by Analysts at Barclays

Barclays assumed coverage on shares of Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) in a research report issued on Tuesday, MarketBeat.com reports. The brokerage set an “underweight” rating and a $8.00 price target on the stock.…

Defense World·Oct 8Negative

Intellia Therapeutics (NASDAQ:NTLA) Now Covered by Analysts at Barclays

Research analysts at Barclays began coverage on shares of Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) in a note issued to investors on Tuesday, MarketBeat reports. The brokerage set a “strong sell” rating and a $8.00 price target…

Defense World·Oct 7Negative

Intellia Therapeutics (NASDAQ:NTLA) CAO Michael Dube Sells 1,864 Shares of Stock

NASDAQ:NTLA opened at $12.37 on Wednesday. The stock has a market capitalization of $1.73 billion, a PE ratio of -3.68 and a beta of 1.80. Intellia Therapeutics, Inc. has a 1-year low of $7.95 and a 1-year high of $28.25. The firm has a…

@kalkineus·Oct 6

Intellia Therapeutics VP Michael P. Dube Executes Mandatory Sale of 1,864 Shares for Tax Withholding on October 2, 2026

Michael P. Dube, Vice President and Chief Accounting Officer at Intellia Therapeutics, Inc. (NASDAQ:NTLA) NTLA (NASDAQ:NTLA) , submitted a Form 4 on October 6, 2026, reporting the mandatory sale of 1,864 common stock shares on October 2,…

@StockTitan_net·Oct 5

Intellia Therapeutics officer proposes $736K sale

Officer Eliana Clark proposes selling 57,750 Intellia Therapeutics (Nasdaq: NTLA) shares. Stock Titan Intellia Therapeutics officer proposes $736K sale The notice also reports that Eliana Clark sold 10,964 common shares on August 10, 2026,…

From articles in the 4Search news index.

In the news

13mentions in 30 days

13with it in the headline

Mixedsentiment

Mentioned with

Intellia11Intellia Therapeutics, Inc.9Nvidia5TD Cowen5Manila Times4Weiss Ratings4Bank of America3Barclays3

People in the coverage

Intellia11Kim Johansen7John Leonard6Sarita Garza6Danessa Lincoln5Marketbeat5

Themes

Healthcare9Therapeutics7Biotechnology3SEC Filings35635(C)(4)2Announces2Canada2Canadian Finance2

Most coverage from

1. defenseworld.net4
2. quiverquant.com2
3. themarketsdaily.com2
4. globenewswire.com1
5. ir.intelliatx.com1

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.